A multi-center, open-label, two-part study to investigate the effect of renal function and hemodialysis on the pharmacokinetics of the novel β-lactamase inhibitor nacubactam
Antimicrobial Agents and Chemotherapy · 03.06.2026 · 70 (6)
DOI: 10.1128/aac.00113-26 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.06.2026. Verfasst von Jun Morita und 7 weiteren Autor:innen. Beteiligte Einrichtung: Meiji Seika Pharma Co. Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, beta-Lactamase Inhibitors, Renal Dialysis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F. Hoffmann-La Roche, Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response.
Abstract (Originalsprache)
Nacubactam is a novel bicyclic non-β-lactam β-lactamase inhibitor that acts as a penicillin-binding protein (PBP-2) active antibacterial, almost exclusively cleared by renal excretion. This study assessed the effect of renal function and hemodialysis on nacubactam pharmacokinetics following a single intravenous (IV) 1 g infusion. Part 1 included three subjects with normal renal function, and six each with mild, moderate, or severe renal impairment; Part 2 included eight subjects with end-stage renal disease undergoing hemodialysis. We observed a strong linear relationship between renal function and both nacubactam total clearance and renal clearance. Compared with subjects with normal renal function, mean nacubactam total clearance was 49%, 73%, and 85% lower among subjects with mild, moderate, and severe renal impairment, respectively, and renal clearance was 42%, 70%, and 90% lower. Nacubactam systemic exposure was correspondingly greater in subjects with impaired renal function. Compared with the normal renal function group, AUC 0-inf was 2-fold, 3.7-fold, and 6.6-fold higher in the mild, moderate, and severe impairment groups, respectively. Similar results were observed across four different methods of estimating renal clearance. Nacubactam was cleared by hemodialysis, with more than 60% of a single dose eliminated during a 4-h dialysis session. Renal impairment had no apparent effect on the safety profile of nacubactam, and a single 1 g dose was well tolerated in all groups. These data can be used to underwrite nacubactam dosing recommendations for patients with impaired renal function, including those receiving renal replacement therapy. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT02975388 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Meiji Seika Pharma Co. Ltd., Tokyo, Japan.
- Roche Pharma Research and Early Development, Roche Innovation Centre New York, Little Falls, New Jersey, USA.
- Global Product Development, Roche Products Limited, Welwyn Garden City, United Kingdom.
- Roche Pharma Research and Early Development, Roche Innovation Centre New York, New York, New York, USA.
- Certara Drug Development Solutions, Certara, Sheffield, United Kingdom.
ORCID-Profile: Jun Morita, Navita L Mallalieu
Förderung
- F. Hoffmann-La Roche
- Biomedical Advanced Research and Development Authority
- Administration for Strategic Preparedness and Response
Zitieren
APA
Morita, J., Ishiwata, K., Matsumoto, S., Rodriguez, I., Patel, K., Attley, G., Mallalieu, N. L., & Bentley, D. (2026). A multi-center, open-label, two-part study to investigate the effect of renal function and hemodialysis on the pharmacokinetics of the novel β-lactamase inhibitor nacubactam. Antimicrobial Agents and Chemotherapy, 70(6). https://doi.org/10.1128/aac.00113-26
Vancouver
Morita J, Ishiwata K, Matsumoto S, Rodriguez I, Patel K, Attley G, et al. A multi-center, open-label, two-part study to investigate the effect of renal function and hemodialysis on the pharmacokinetics of the novel β-lactamase inhibitor nacubactam. Antimicrobial Agents and Chemotherapy. 2026;70(6). doi:10.1128/aac.00113-26
BibTeX
@article{Morita2026,
author = {Morita, Jun and Ishiwata, Kazuya and Matsumoto, Shogo and Rodriguez, Ignacio and Patel, Katie and Attley, Gemma and Mallalieu, Navita L and Bentley, Darren},
title = {A multi-center, open-label, two-part study to investigate the effect of renal function and hemodialysis on the pharmacokinetics of the novel β-lactamase inhibitor nacubactam},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {6},
doi = {10.1128/aac.00113-26}
}
EUVIMED